Exosome Diagnostics, Inc.

Exosome Therapeutics and Diagnostics Pipeline Shows Promising Growth

8 months ago

• The exosome market is experiencing rapid growth, driven by advancements in liquid biopsy, precision medicine, and regenerative medicine. • Over 70 companies are developing 75+ exosome-based therapies, with several candidates in various clinical trial phases. • Exosome-based diagnostics are gaining traction, with two products already receiving Fast Track approval from the U.S. FDA. • The first exosome therapeutics are anticipated by 2029, offering advantages like targeted delivery and reduced side effects.